Latest News and Press Releases

WATERTOWN, Mass., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...

– Selecta eligible to receive upfront and milestone payments of over $240 million – – AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and...

– Top-line statistical results expected mid-2020 – – Company to meet with FDA in January 2020 regarding Phase 3 clinical development plan – WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) --...

WATERTOWN, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...

– Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company’s ImmTOR™...

WATERTOWN, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...

– Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies – –...

- Compelling preclinical data presented at the European Society of Gene and Cell Therapy Annual Congress demonstrates the potential for redosing in AAV-mediated gene therapy; announced strategic...

WATERTOWN, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...

WATERTOWN, Mass., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies...